Currently in my 4-8 weeks break time away from research. Last research cycle, TB-500 was administered every 5 days @5mg at a time. For the next research cycle, would the TB4 dosage stay the same as TB-500? Additional peps were BPC-157 .5mg twice per day, mots-c 5mg every 5 days, copper 2mg daily and Reta every Saturday 1mg and went up weekly and currently @5mg. This Saturday will start titrating off by reducing by 1-2mg per week. Do plan to add cartalax if I can find it. Would actually like to do it during my current off week but can’t seem to find a kit with good COAs. Thoughts would be appreciated

I have added a community alert to their vendor page on here.

@Commander I did the same thing. Ordered one. Completed order. The. Soon added the other order and it combined it since it was over the weekend and the order had not been processed

@randy where are you getting tb4?

@MikeMiranda oh I wish that was me. I went from researching at 3ml's bac, and a lump at a time, saw 5 ml's was where alot of people find relief but not me either. At 6ml's it's not too bad, no big deal. But now I'm wondering maybe I just do 8ml's or 9 like above and not have any. I do feel lucky to be able to research up to 5mg mots-c at a time. Some people can't research it at all.

@Nolan Based on my reading and practice, it is 500mcg (each) daily for maintenance and up to 1mg per day for injury repair. There are some folks here who research much higher levels..

For research use only. Not medical advice. Overview BPC-157 is a synthetic 15–amino-acid peptide studied for potential effects on tissue repair, inflammation modulation, and gastrointestinal protection. Human clinical evidence is still limited, so researchers rely on conservative dosing patterns derived from preclinical data. Subcutaneous administration is the most common route in systemic research models. Daily Dosing Protocol (Subcutaneous) Standard Daily Range 200–600 mcg once daily Escalate gradually to assess individual response and tolerance. Titration Schedule Weeks 1–2 200 mcg daily Useful as a gentle introduction, particularly when monitoring sensitivity. Weeks 3–4 400 mcg daily Represents the common working dose for generalized healing or recovery-focused protocols. Weeks 5–8+ 600 mcg daily Higher end of typical daily research use; often maintained for prolonged tissue-repair goals. Timing Once daily, at any consistent time. Some researchers prefer morning fasted dosing; others use evening to complement recovery protocols — timing is flexible. Cycle Length Standard BPC-157 research cycles: 4–8 weeks, depending on the model Optional 2–4 week break before repeating Shorter cycles may be used for acute-injury research models Chronic continuous use is less common due to limited long-term human data. Common Research Notes BPC-157 is generally well tolerated, though individual sensitivity varies. Some subjects report improvements in soft-tissue recovery, joint comfort, or GI stability within 1–3 weeks. Effects may plateau after several weeks, which is why cycles often cap at 8 weeks. Some researchers combine BPC-157 with TB-500 or GHK-Cu for injury-specific protocols.

@diegoc He did not bring any receipts...Not that I am protecting TB but putting him down like that and then making it appear that you are sending links that show all that you said, which they are not, is WEAK at best. If you are going to say someone is a fake and has insurance fraud etc etc then show those receipts and don't just regurgitate what you may have heard or read...It makes you look small and petty. Just my .02